To explain discordant clinical and molecular subtyping, we assessed 80-GS molecular subtype, total ER mRNA expression and ER variant mRNA expression in 84 ER+/Basal and 48 ER+/Luminal B breast cancers in a prospective trial (NBRST registry trial). This evidence concerns the gene ESR1 and breast carcinoma.